All In Biotech

NDA 209817 · Paratek Pharms

Nuzyra

Omadacycline Tosylate · Intravenous · Tetracycline-class Antibacterial

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 2, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

21

7 Phase 3, 0 recruiting

FAERS reports

1,716

997 serious, 118 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Community-Acquired Bacterial Pneumonia NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae , Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae , Haemophilus parainfluenzae , Klebsiella pneumoniae, Legionella pneumophila , Mycoplasma pneumoniae, and Chlamydophila pneumoniae . 1.2 Acute Bacterial Skin and Skin Structure Infections NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis , Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus , S. intermedius , and S. constellatus ), Enterococcus faecalis , Enterobacter cloacae, and Klebsiella pneumoniae. 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and...

Mechanism: NUZYRA is an antibacterial drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 13, 2026 Supplement 18 · Efficacy LetterLabel
  • May 27, 2021 Supplement 10 · Efficacy LetterLabel
  • Oct 2, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • NUZYRA · OMADACYCLINE TOSYLATE EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omadacycline" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use454
  • nausea268
  • vomiting166
  • drug ineffective128
  • diarrhoea125
  • incorrect product administration duration95
  • dyspnoea88
  • rash86
  • fatigue73
  • death72
  • incorrect dose administered69
  • hospitalisation62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
201935
2020109
2021145
2022152
2023296
2024348
2025399
2026231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuzyra* (Omadacycline Tosylate)

2024 spending

$107M

Beneficiaries

4,748

9,988 claims

Per beneficiary

$22,456

$245.48 per unit

View as table
YearSpending
2020$11,447,781
2021$23,584,013
2022$44,132,806
2023$73,196,529
2024$106,622,302

Part B: Nuzyra (Omadacycline Tosylate) · HCPCS J0121

2024 spending

$3.7M

Beneficiaries

445

8,697 claims

Per beneficiary

$8,385

2024 ASP limit $3.77 per unit

View as table
YearSpending
2020$1,069,624
2021$1,621,501
2022$1,692,373
2023$2,388,812
2024$3,731,518

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Paratek Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.